Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG

First Line ◽

Interventional Study ◽

First Line Therapy ◽

Line Therapy ◽

Systemic Antibiotics

Impact of surgical resection of liver metastases on outcome of patients with KRAS-wildtype exon 2 (KRAS-wt) metastatic colorectal carcinoma (mCRC) treated with a cetuximab-based first-line therapy - Interim analysis of the German non-interventional study ERBITAG

Annals of Oncology ◽

10.1093/annonc/mdw370.39 ◽

2016 ◽

Vol 27 ◽

pp. vi162

Author(s):

U. Neumann ◽

T. Goehler ◽

C. Hering-Schubert ◽

J. Janssen ◽

S. Sahm ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Liver Metastases ◽

Surgical Resection ◽

Interim Analysis ◽

First Line ◽

Interventional Study ◽

Exon 2 ◽

First Line Therapy ◽

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

ESMO Open ◽

10.1016/j.esmoop.2021.100062 ◽

2021 ◽

Vol 6 (2) ◽

pp. 100062

Author(s):

J. Sastre ◽

P. García-Alfonso ◽

J.M. Viéitez ◽

M.T. Cano ◽

F. Rivera ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Phase Ii ◽

Tumour Cells ◽

Circulating Tumour Cells ◽

Wild Type ◽

First Line ◽

Pik3ca Mutations ◽

First Line Therapy ◽

Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma

Cancer ◽

10.1002/cncr.21411 ◽

2005 ◽

Vol 104 (9) ◽

pp. 1871-1884 ◽

Cited By ~ 28

Author(s):

Bruce E. Hillner ◽

Deborah Schrag ◽

Daniel J. Sargent ◽

Charles S. Fuchs ◽

Richard M. Goldberg

Keyword(s):

Cost Effectiveness ◽

Colorectal Carcinoma ◽

First Line ◽

First Line Therapy ◽

Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear

Future Oncology ◽

10.2217/14796694.4.6.741 ◽

2008 ◽

Vol 4 (6) ◽

pp. 741-744 ◽

Cited By ~ 4

Author(s):

Alastair CJ Windsor ◽

Richard Cohen ◽

Long R Jiao ◽

Justin Stebbing

Keyword(s):

Colorectal Carcinoma ◽

First Line ◽

First Line Therapy ◽

O-020 Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

Annals of Oncology ◽

10.1093/annonc/mdv235.19 ◽

2015 ◽

Vol 26 ◽

pp. iv115 ◽

Cited By ~ 3

Author(s):

R. Garcia-Carbonero ◽

R. Obermannova ◽

G. Bodoky ◽

J. Prausova ◽

T.-E. Ciuleanu ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Carcinoma ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70127-0 ◽

2015 ◽

Vol 16 (5) ◽

pp. 499-508 ◽

Cited By ~ 406

Author(s):

Josep Tabernero ◽

Takayuki Yoshino ◽

Allen Lee Cohn ◽

Radka Obermannova ◽

Gyorgy Bodoky ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Second Line ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Multicentre Phase ◽

First Line Therapy ◽

P3.02a-015 Ceritinib as First-Line Therapy in Patients with ALK-Rearranged Non-Small Cell Lung Cancer: ASCEND-1 Subgroup Analysis

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2016.11.1645 ◽

2017 ◽

Vol 12 (1) ◽

pp. S1169-S1170

Author(s):

Daniel Shao-Weng Tan ◽

Enriqueta Felip ◽

Laura Qm Chow ◽

Sunil Sharma ◽

Patrick Urban ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Subgroup Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

European Journal of Cancer ◽

10.1016/s0959-8049(16)31030-9 ◽

2015 ◽

Vol 51 ◽

pp. S365

Author(s):

E. Van Cutsem ◽

R. Obermannova ◽

G. Bodoky ◽

J. Prausová ◽

R. García-Carbonero ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Combination Therapy ◽

Folinic Acid ◽

Subgroup Analysis ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Kras Status ◽

Phase Iii Study

Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status

Annals of Oncology ◽

10.1093/annonc/mdv340.05 ◽

2015 ◽

Vol 26 ◽

pp. vi37 ◽

Cited By ~ 2

Author(s):

A. Sobrero ◽

L. Latini ◽

C. Barone ◽

F. Capuzzo ◽

M. Banzi ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Combination Therapy ◽

Subgroup Analysis ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Multicenter Phase ◽

Kras Status ◽

Phase Iii Study

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.3568 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 3568-3568

Author(s):

Stefan Kasper ◽

Johannes Meiler ◽

Heike Knipp ◽

Thomas Hoehler ◽

Peter Reimer ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Primary Endpoint ◽

Subgroup Analysis ◽

Wild Type ◽

First Line ◽

Exon 2 ◽

First Line Therapy ◽